Most patients had poor prognosis features, including stage IV disease (85%), intermediate or high-risk MIPI (56%), blastoid MCL (59%), high Ki67 (69%), or TP53 mutation (17%). The gene discussed is MKI67; the disease is mantle cell lymphoma.